Loading…

A population-based analysis on the use of therapeutic plasma exchange and intravenous immunoglobulin in heparin-induced thrombocytopenia

In heparin-induced thrombocytopenia (HIT), selected patients are treated with therapies directed at the immune response, intravenous immunoglobulin (IVIG) and therapeutic plasma exchange (TPE). To determine IVIG and TPE characteristics and outcomes in HIT, we analyzed the National Inpatient Sample (...

Full description

Saved in:
Bibliographic Details
Published in:Thrombosis research 2021-05, Vol.201, p.6-14
Main Authors: Soares Ferreira Júnior, Alexandre, Boyle, Stephen H., Kuchibhatla, Maragatha, Onwuemene, Oluwatoyosi A.
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:In heparin-induced thrombocytopenia (HIT), selected patients are treated with therapies directed at the immune response, intravenous immunoglobulin (IVIG) and therapeutic plasma exchange (TPE). To determine IVIG and TPE characteristics and outcomes in HIT, we analyzed the National Inpatient Sample (NIS) database. In a population-based analysis of the NIS, we identified hospital discharges of adult patients with a HIT diagnosis. A two-level statistical analysis was performed comparing cases as follows 1) IVIG or TPE vs. none; and 2) IVIG vs. TPE. For each analysis, the primary outcome was in-hospital mortality. Secondary outcomes were thrombotic events, major bleeding, infections, hospital length of stay, and total charges. Among 22,152 discharges with a HIT diagnosis, 77 (0.34%) and 52 (0.23%) received TPE and IVIG, respectively. In the first level analysis of TPE or IVIG vs. no treatment, TPE or IVIG treatment was associated with a higher likelihood of in-hospital mortality (OR = 1.85; 95%CI: 1.13–3.03, p = 0.0104), major bleeding (OR = 1.91; 95%CI: 1.25–2.93, p = 0.0030), gastrointestinal bleeding (OR = 1.89; 95%CI: 1.08–3.30, p = 0.0259), and infection (OR = 1.65; 95% CI:1.13–2.41, p = 0.0095). In the second-level analysis comparing IVIG vs. TPE, there were no significant differences in patient characteristics or outcomes in both unadjusted and adjusted analyses. In this population-based analysis of HIT, we found similar outcomes of IVIG and TPE-treated cases. Given the small sample size, future studies are needed to confirm this observation. •A population-based study of IVIG and TPE in HIT.•From 2010 to 2014, the prevalence of TPE and IVIG-treated cases was low.•IVIG and TPE-treated cases had similar characteristics and outcomes.•Worse outcomes of IVIG and TPE-treated cases may suggest severe HIT.•Prospective studies are needed to confirm these observations.
ISSN:0049-3848
1879-2472
DOI:10.1016/j.thromres.2021.02.017